BGBertolt Gust

Bertolt Gust

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bertolt Gust has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Stefanie Siebenberg

    Eberhard-Karls-Universität Tübingen, Pharmazeutische Biologie, Auf der Morgenstelle 8, 72076 Tübingen, Germany

    7 shared publications
  • Harald Gross

    Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen

    6 shared publications
  • Leonard Kaysser

    Pharmaceutical Institute, University of Tübingen, Tübingen, Germany

    6 shared publications
  • Andreas Kulik

    Eberhard Karls University Tübingen Auf der Morgenstelle 28

    5 shared publications
  • Lutz Heide

    Eberhard Karls University Tübingen

    5 shared publications
  • Bernd Kammerer

    Pharmazeutisches Institut, Eberhard-Karls-Universität Tübingen, 72076 Tübingen, Germany,1 Departamento de Biologia Funcional, Universidad de Oviedo, 33006 Oviedo, Spain,2 Department of Pharmaceutical Engineering, Sun Moon University, Asan 336-708, South Korea,3 Zentrum für Biosystemanalyse, Albert-Ludwigs-Universität Freiburg, 79104 Freiburg, Germany4

    4 shared publications

Latest Publications

  • Open Access

    Engineering a production platform for the potent antipseudomonal antibiotic mureidomycin A by reprogramming the pacidamycin biosynthetic gene cluster

    by Panagiota-Hanna Koutsandrea, Richard Sonnengrün, Nils Hauck, Andreas Kulik, Theresa Harbig, Jan-Martin Daniel, Kay Katja Nieselt, Rebecca Jane Miriam Goss, Tanja Schneider, Silja Mordhorst, et al.

    Background: Uridyl peptide antibiotics display potent activity against Pseudomonas aeruginosa , a pathogen causing severe nosocomial infections. The four subclasses—mureidomycins, pacidamycins, napsamycins, and sansanmycins—inhibit the underexplored bacterial target phospho-MurNAc-pentapeptide translocase (MraY). Structurally, these compounds contain a 3’-deoxyuridine linked to a central diaminobutyric acid. The latter is situated within a pseudo tetra- or pentapeptide moiety, assembled by a non-ribosomal peptide synthetase machinery. The subclasses are distinguished by variations in the incorporated amino acids. Native producer strains typically synthesize numerous different uridyl peptide antibiotics in low yields. Since the pacidamycin gene cluster displays higher overall yields compared to the napsamycin cluster in identical expression systems, we aimed to reprogram it into a selective production platform for the highly bioactive mureidomycin A. This approach is intended to streamline isolation processes and support hit-to-lead optimization. Results: Streptomyces albus J1074 was identified as the most promising host for heterologous expression of the pacidamycin gene cluster. Subsequently, media screening and precursor feeding were conducted, and regulators of closely related gene clusters were introduced into the heterologous host. The overexpression of the NpsM regulator of the napsamycin gene cluster increased production significantly. Next, the pacidamycin gene cluster was engineered to produce the more potent mureidomycins. Variable positions of the peptide moiety were individually targeted by domain or module swaps of the non-ribosomal peptide synthetase machinery. More specifically, these were replaced by homologs of the napsamycin gene cluster, resulting in strains mainly producing sansanmycin A or mureidomycin A. Promoter engineering enhanced mureidomycin A production in the final strain, correlating with increased transcription levels in RNA sequencing experiments on an intermediate strain harboring the same promoters. Conclusions: Hybrid uridyl peptide antibiotic gene clusters were constructed by genetically engineering the pacidamycin cluster, demonstrating the versatility of these clusters. While the native pacidamycin cluster only produced pacidamycin D and S, the final strain yields the more bioactive mureidomycin A and Met-pacidamycin 5. Additionally, sansanmycin A ( syn. Met-pacidamycin 4) can be isolated from an intermediate construct of this study. This expands the access to different analogs and highlights further engineering potential, which will facilitate the future development of these promising antibiotics.

  • Open Access

    A Biotechnological Platform for Gram-Scale Production of Mureidomycin A

    by Panagiota-Hanna Koutsandrea, Richard Sonnengrün, Nils Hauck, Andreas Kulik, Harald Gross, Silja Mordhorst, Bertolt Gust

    Mureidomycin A is a uridyl peptide antibiotic with potent bioactivity against the Gram-negative pathogen Pseudomonas aeruginosa. Crucial bottlenecks impeding further drug development include low compound production in native producers and heterologous hosts, as well as the formation of numerous derivatives, which further reduces the yield of the target compound. By analyzing different production hosts and deleting single genes, a production platform for mureidomycin A was developed in this study. The production of several derivatives was reduced or abolished, facilitating compound isolation. While mureidomycin A was previously produced in trace amounts, the final strain yields ∼1.4 g/L, enabling future preclinical studies.

  • Open Access

    The TetR-like regulator Sco4385 and Crp-like regulator Sco3571 modulate heterologous production of antibiotics in Streptomyces coelicolor M512

    by Sarah Wilcken, Panagiota-Hanna Koutsandrea, Tomke Bakker, Andreas Kulik, Tim Orthwein, Mirita Franz-Wachtel, Theresa Harbig, Kay Katja Nieselt, Karl Forchhammer, Heike Brötz-Oesterhelt, et al.

    Heterologous expression in well-studied model strains is a routinely applied method to investigate biosynthetic pathways. Here, we pursue a comparative approach of large-scale DNA-affinity-capturing assays (DACAs) coupled with semi-quantitative mass spectrometry (MS) to identify putative regulatory proteins from Streptomyces coelicolor M512, which bind to the heterologously expressed biosynthetic gene clusters (BGCs) of the liponucleoside antibiotics caprazamycin and liposidomycin. Both gene clusters share an almost identical genetic arrangement, including the location of promoter regions, as detected by RNA sequencing. A total of 2,214 proteins were trapped at the predicted promoter regions, with only three binding to corresponding promoters in both gene clusters. Among these, the overexpression of a yet uncharacterized TetR-family regulator (TFR), Sco4385, increased caprazamycin but not liposidomycin production. Protein–DNA interaction experiments using biolayer interferometry confirmed the binding of Sco4385 to P cpz10 and P lpmH at different locations within both promoter regions, which might explain its functional variance. Sequence alignment allowed the determination of a consensus sequence present in both promoter regions, to which Sco4385 was experimentally shown to bind. Furthermore, we found that the overexpression of the Crp regulator, Sco3571, leads to a threefold increase in caprazamycin and liposidomycin production yields, possibly due to an increased expression of a precursor pathway. IMPORTANCE: Streptomycetes are well-studied model organisms for the biosynthesis of pharmaceutically, industrially, and biotechnologically valuable metabolites. Their naturally broad repertoire of natural products can be further exploited by heterologous expression of biosynthetic gene clusters (BGCs) in non-native host strains. This approach forces the host to adapt to a new regulatory and metabolic environment. In our study, we demonstrate that a host regulator not only interacts with newly incorporated gene clusters but also regulates precursor supply for the produced compounds. We present a comprehensive study of regulatory proteins that interact with two genetically similar gene clusters for the biosynthesis of liponucleoside antibiotics. Thereby, we identified regulators of the heterologous host that influence the production of the corresponding antibiotic. Surprisingly, the regulatory interaction is highly specific for each biosynthetic gene cluster, even though they encode largely structurally similar metabolites.


  • Open Access

    Origin of the 3-methylglutaryl moiety in caprazamycin biosynthesis

    by Daniel Bär, Benjamin Konetschny, Andreas Kulik, Houchao Xu, Davide Paccagnella, Patrick Beller, Nadine Ziemert, Jeroen S. Dickschat, Bertolt Gust

    Background: Caprazamycins are liponucleoside antibiotics showing bioactivity against Gram-positive bacteria including clinically relevant Mycobacterium tuberculosis by targeting the bacterial MraY-translocase. Their chemical structure contains a unique 3-methylglutaryl moiety which they only share with the closely related liposidomycins. Although the biosynthesis of caprazamycin is understood to some extent, the origin of 3-methylglutaryl-CoA for caprazamycin biosynthesis remains elusive. Results: In this work, we demonstrate two pathways of the heterologous producer Streptomyces coelicolor M1154 capable of supplying 3-methylglutaryl-CoA: One is encoded by the caprazamycin gene cluster itself including the 3-hydroxy-3-methylglutaryl-CoA synthase Cpz5. The second pathway is part of primary metabolism of the host cell and encodes for the leucine/isovalerate utilization pathway (Liu-pathway). We could identify the liu cluster in S. coelicolor M1154 and gene deletions showed that the intermediate 3-methylglutaconyl-CoA is used for 3-methylglutaryl-CoA biosynthesis. This is the first report of this intermediate being hijacked for secondary metabolite biosynthesis. Furthermore, Cpz20 and Cpz25 from the caprazamycin gene cluster were found to be part of a common route after both individual pathways are merged together. Conclusions: The unique 3-methylglutaryl moiety in caprazamycin originates both from the caprazamycin gene cluster and the leucine/isovalerate utilization pathway of the heterologous host. Our study enhanced the knowledge on the caprazamycin biosynthesis and points out the importance of primary metabolism of the host cell for biosynthesis of natural products.


  • The substrate scope of dehydratases in antibiotic biosynthesis and their application in kinetic resolutions

    by Zhiyong Yin, Daniel Bär, Bertolt Gust, Jeroen S. Dickschat

    Nine dehydratases involved in the biosynthesis of secondary metabolites in addition to FabZ from fatty acid biosynthesis were investigated for their substrate scope using a panel of N-acetylcysteamine (SNAC) thioesters. The best performing enzyme BorDH2 was applied in kinetic resolutions.


  • Open Access

    Convergent evolution of plant pattern recognition receptors sensing cysteine-rich patterns from three microbial kingdoms

    by Yuankun Yang, Christina E. Steidele, Birgit Loeffelhardt, Dagmar E. Kolb, Thomas Leisen, Weiguo Zhang, Christina Ludwig, Georg Felix, Michael F. Seidl, Thorsten Nuernberger, et al.

    The Arabidopsis thaliana receptor-like protein RLP30 contributes to immunity against the fungal pathogen Sclerotinia sclerotiorum . Here we identified the RLP30-ligand as a small cysteine-rich protein (SCP) that occurs in many fungi and oomycetes and is also recognized by the Nicotiana benthamiana RLP RE02. However, RLP30 and RE02 share little sequence similarity and respond to different parts of the native/folded protein. Interestingly, some Brassicaceae other than Arabidopsis also respond to a linear SCP peptide, suggesting that SCP is an eminent immune target that led to the convergent evolution of distinct immune receptors in plants. Surprisingly, RLP30 shows a second ligand specificity for a SCP-nonhomologous protein secreted by bacterial Pseudomonads. RLP30 expression in N. tabacum resulted in lower susceptibility to bacterial, fungal and oomycete pathogens, thus demonstrating that detection of immunogenic patterns by Arabidopsis RLP30 is involved in defense against pathogens from three microbial kingdoms.

  • Open Access

    Mycothiol Peroxidase Activity as a Part of the Self-Resistance Mechanisms against the Antitumor Antibiotic Cosmomycin D

    by Roger D. Castillo Arteaga, Leandro M. Garrido, Brandán Pedre, Irina Helmle, Harald Gross, Bertolt Gust, Gabriel Padilla

    Anthracycline compounds are DNA intercalating agents widely used in cancer chemotherapeutic protocols. This work focused on the self-resistance mechanisms developed by the cosmomycin-producing bacterium Streptomyces olindensis .


  • Open Access

    Genetic Engineering in Combination with Semi‐Synthesis Leads to a New Route for Gram‐Scale Production of the Immunosuppressive Natural Product Brasilicardin A

    by Alma Botas, Michael Eitel, Paul N. Schwarz, Anina Buchmann, Paula Costales, Luz Elena Núñez, Jesús Cortés, Francisco Morís, Michał Krawiec, Marcin Wolański, et al.

    Brasilicardin A (1) consists of an unusual anti/syn/anti‐perhydrophenanthrene skeleton with a carbohydrate side chain and an amino acid moiety. It exhibits potent immunosuppressive activity, yet its mode of action differs from standard drugs that are currently in use. Further pre‐clinical evaluation of this promising, biologically active natural product is hampered by restricted access to the ready material, as its synthesis requires both a low‐yielding fermentation process using a pathogenic organism and an elaborate, multi‐step total synthesis. Our semi‐synthetic approach included a) the heterologous expression of the brasilicardin A gene cluster in different non‐pathogenic bacterial strains producing brasilicardin A aglycone (5) in excellent yield and b) the chemical transformation of the aglycone 5 into the trifluoroacetic acid salt of brasilicardin A (1 a) via a short and straightforward five‐steps synthetic route. Additionally, we report the first preclinical data for brasilicardin A.


  • Open Access

    Genetic Engineering in Combination with Semi‐Synthesis Leads to a New Route for Gram‐Scale Production of the Immunosuppressive Natural Product Brasilicardin A

    by Alma Botas, Michael Eitel, Paul N. Schwarz, Anina Buchmann, Paula Costales, Luz Elena Núñez, Jesús Cortés, Francisco Morís, Michał Krawiec, Marcin Wolański, et al.

    Brasilicardin A (1) consists of an unusual anti/syn/anti‐perhydrophenanthrene skeleton with a carbohydrate side chain and an amino acid moiety. It exhibits potent immunosuppressive activity, yet its mode of action differs from standard drugs that are currently in use. Further pre‐clinical evaluation of this promising, biologically active natural product is hampered by restricted access to the ready material, as its synthesis requires both a low‐yielding fermentation process using a pathogenic organism and an elaborate, multi‐step total synthesis. Our semi‐synthetic approach included a) the heterologous expression of the brasilicardin A gene cluster in different non‐pathogenic bacterial strains producing brasilicardin A aglycone (5) in excellent yield and b) the chemical transformation of the aglycone 5 into the trifluoroacetic acid salt of brasilicardin A (1 a) via a short and straightforward five‐steps synthetic route. Additionally, we report the first preclinical data for brasilicardin A.

  • Identification of Novel α-Pyrones from Conexibacter woesei Serving as Sulfate Shuttles

    by Franziska Wiker, Martin Konnerth, Irina Helmle, Andreas Kulik, Leonard Kaysser, Harald Gross, Bertolt Gust

    Pyrones comprise a structurally diverse class of compounds. Although they are widespread in nature, their specific physiological functions remain unknown in most cases. We recently described that triketide pyrones mediate the sulfotransfer in caprazamycin biosynthesis. Herein, we report the identification of conexipyrones A–C, three previously unrecognized tetra-substituted α-pyrones, from the soil actinobacterium Conexibacter woesei. Insights into their biosynthesis via a type III polyketide synthase were obtained by feeding studies using isotope-enriched precursors. In vitro assays employing the genetically associated 3′-phosphoadenosine-5′-phosphosulfate (PAPS)-dependent sulfotransferase CwoeST revealed conexipyrones as the enzymes’ genuine sulfate acceptor substrates. Furthermore, conexipyrones were determined to function as sulfate shuttles in a two-enzyme assay, because their sulfated derivatives were accepted as donor molecules by the PAPS-independent arylsulfate sulfotransferase (ASST) Cpz4 to yield sulfated caprazamycin intermediates.